)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Onward Medical
Onward Medical (ONWD) investor relations material
Onward Medical Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary3 Nov, 2026
Executive summary
Q3 revenue was €2.5M, including €2.0M from ARC-EX; 88 systems were sold or supplied via paid evaluation, up 120% YoY; quarter-end cash was €73.4M.
Clinical programs advanced: Empower BP enrolled 31 participants; EIGER reported first chronic and subacute SCI implants; ReeVoid completed first-in-human ARC-IM bladder-control use; two additional PD-HemON participants were treated.
Financial highlights
Q3 revenue was €2.5M, including €2.0M of ARC-EX product revenue.
€8.1M was used during Q3; the cash-burn figure included the senior secured note refinancing effect.
Net cash was €73.4M as of September 30, 2026, including cash, cash equivalents, and current fixed-term deposits.
Outlook and guidance
Empower BP interim analysis remains on track for spring 2027 and will determine whether the study can stop at 60 participants or continue to 112.
Regulatory approval for Empower BP is anticipated by end-2028, followed by commercial launch.
No 2027 financial guidance was provided; H1 spending was described as a more representative reference than Q3, with some pivotal-study costs expected to tail off in 2027.
ARC-IM mobility pivotal study could begin around 2028–2029, depending on EIGER data, patient-response insights, endpoint design, and follow-up evidence.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Onward Medical
- Breakthrough neuromodulation platforms drive clinical, commercial, and pipeline momentum in SCI.ONWD
Company presentation - Revenue up 250% year-over-year to €4.2M, with strong ARC-EX sales and extended cash runway.ONWDQ2 2026
- Innovative neuromodulation platforms drive clinical and commercial progress in SCI rehabilitation.ONWDCorporate presentation
- Q1 2026 revenue hit EUR 2.0M, home use outpaced clinics, and cash runway extended to 2028.ONWDQ1 2026 TU
- EUR 5.4M revenue, 117 ARC-EX units sold, strong US/EU adoption, and major regulatory progress.ONWDH2 2025
- Breakthrough spinal cord therapies drive strong sales, clinical progress, and major upcoming milestones.ONWDLife Sciences Virtual Investor Forum 2025
- Strong Q1 US ARC-EX sales, €50.5M cash, and clinical advances drive growth outlook.ONWDQ1 2025 TU
- €50M raised, exclusive BCI rights secured, and FDA clearance expected for ARC-EX.ONWDQ3 2024 TU
- FDA clearance and US launch for ARC-EX expected Q4, with €32.1M cash and new financing secured.ONWDH1 2024
Next Onward Medical earnings date
Q4 202616 Feb, 2027
Onward Medical
Next Onward Medical earnings date
Q4 202616 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Onward Medical N.V. is a medical technology company focused on developing innovative therapies to restore movement, function, and independence for people with spinal cord injuries. It has developed two main technology platforms: ARCIM, an implantable neurostimulation system, and ARCEX, a non-invasive transcutaneous system. These technologies are designed to improve or restore motor functions and independence in individuals affected by spinal cord injuries through targeted spinal cord stimulation. The company is engaged in ongoing clinical trials to validate and expand the application of its technologies. Onward Medical N.V. is headquartered in Eindhoven, Netherlands, and its shares are listed on Euronext Brussels and Euronext Amsterdam.